Your search for Warfarin returned 111 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove
Post remove

Your search for Warfarin returned 111 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Dabigatran Comparable to Warfarin in DVT/PE Trial

Boehringer Ingelheim announced results from the RE-COVER II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
News

Rivaroxaban Compared With Warfarin in Morbidly Obese Patients With VTE

Results from a new real-world study evaluating rivaroxaban (Xarelto; Janssen), a factor Xa inhibitor, in morbidly obese patients were recently published in Thrombosis Research. The retrospective cohort study analyzed data from 2 US claims databases (Truven MarketScan Commercial Claims and Encounters database and MarketScan Medicare Supplemental database) to evaluate the clinical and health/economic outcomes of…
News

Study: Xarelto Lowers Hospital Admissions, Costs for DVT Patients

Patients treated with Xarelto (rivaroxaban; Janssen) for deep vein thrombosis (DVT) had less frequent hospital admissions than those treated with standard low molecular weight heparin (LMWH) and warfarin, according to study data presented at the Hospital Medicine 2015 Congress.
News

First-of-Kind Implant to Reduce Stroke in High-Risk Patients Approved

Boston Scientific announced that the Food and Drug Administration (FDA) has approved WATCHMAN Left Atrial Appendage Closure Device to reduce the risk of stroke in high-risk patients with non-valvular atrial fibrillation who are looking for an alternative to long-term warfarin therapy.
Drugs in the Pipeline

FDA to Review New Warfarin Formulation

Accu-Break Pharmaceuticals (ABP) announced that the Food & Drug Administration (FDA) has accepted for filling the New Drug Application (NDA) for Warfarin Potassium.
American College of Cardiology 2013

Dabigatran Safe and Effective Post-Atrial Fibrillation Ablation

At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, leading cardiologists presented that the use of dabigatran following ablation for atrial fibrillation resulted in no major post-procedural complications.
Uncategorized

FDA: Pradaxa vs. Warfarin Study Results Announced

The FDA announced the results of a new study on Medicare patients comparing Pradaxa (dabigatran etexilate mesylate; Boehringer Ingelheim Pharmaceuticals) vs. warfarin for risk of ischemic or clot-related stroke, bleeding in the brain, major gastrointestinal (GI) bleeding, myocardial infarction (MI), and death.